Intensive Postpartum Antihypertensive Treatment

RECRUITING

I'm interested ...!!

The long-term goal of our work is to evaluate the effect of intensive postpartum blood pressure control on maternal cardiovascular health, risk of chronic hypertension, and reversal of vascular dysfunction generated by hypertensive disorders of pregnancy, thus attenuating the lifelong trajectory of cardiovascular disease risk.

Conditions:

🦠 Hypertensive Disorder of Pregnancy

🗓️ Study Start (Actual) 1 September 2023

🗓️ Primary Completion (Estimated) March 2026

✅ Study Completion (Estimated) March 2026

👥 Enrollment (Estimated) 60

🔬 Study Type INTERVENTIONAL

📊 Phase PHASE3

Locations:

📍 Milwaukee, Wisconsin, United States

📋 Eligibility Criteria

Description

Inclusion Criteria:

* HDP diagnosis (gestational hypertension or preeclampsia) according to ACOG guidelines
* Postpartum day 0-3 and prior to discharge
* Able to communicate in English or in Spanish
* Age 18 - 45

Exclusion Criteria:

* Pre-gestational hypertension
* Pre-gestational diabetes ( type 1 or type 2)
* Intent to transfer postpartum to an outside institution of the participating centers
* Known allergy to nifedipine or other significant contraindication to nifedipine
* Inability or unwillingness to provide informed consent

Ages Eligible for Study: 18 Years to 45 Years (ADULT)

Sexes Eligible for Study: FEMALE

Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted 1 January 2023
First Submitted that Met QC Criteria 16 January 2023
First Posted 18 January 2023

Study Record Updates

Last Update Submitted that Met QC Criteria 4 January 2024
Last Update Posted 5 January 2024
Last Verified January 2024